MariMed Q2 revenue $32.6M (+239% YoY); raises FY2021 guidance to $118M revenue, $32M EBITDA

MARIMED INC.

2021-Q2 EPS reported $0.03 revenue$57,212,220

Revenue $32.6M, up 239% YoY and 32% QoQ; net income $7.6M vs loss $1.1M in Q2 2020.
EBITDA $12.3M (+440% YoY); Adjusted EBITDA $13.9M (43% margin).
Raises FY2021 guidance: revenue to $118M (from $100M), EBITDA to $32M (from $30M); first-time Adj. EBITDA guide of $42M.
Positive operating cash flow $10.8M; working capital $20.9M, up $7.2M from Q1.
Growth driven by wholesale in MA, retail in MA/IL, and branded product licensing in six states.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.